SOCIETY: AGA This session is the second session of the ever-popular and clinically impactful clinical trials sessions in IBD. Insights into novel agents including obefazimod, VTX002. MH002, risankizumab, and mirikizumab will be presented…

Novel Observations in IBD

MONITORING IBD BY INTESTINAL ULTRASOUND DECREASES TIME TO TREATMENT CHANGE AND TIME TO REMISSION IN COMPARISON TO CONVENTIONAL MANAGEMENT: ANALYSIS OF PATIENTS WITH IBD ON MULTIPLE IBD THERAPIES

Epi II: Best of Observational Studies in IBD

SOCIETY: AGA This session highlights the best of the best observational studies in IBD for DDW 2024 and provides clinical relevant and novel insights across the age and clinical spectrum, including wound healing after C-section…

IMIBD Late Breakers and Innovations in IBD

SOCIETY: AGA By popular demand, this new session highlights the best late-breakers submitted to the IBD section and well as innovations in technology and new paradigms of care in IBD